<?xml version='1.0' encoding='utf-8'?>
<document id="22283559"><sentence text="Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers."><entity charOffset="53-69" id="DDI-PubMed.22283559.s1.e0" text="dextromethorphan" /><entity charOffset="70-79" id="DDI-PubMed.22283559.s1.e1" text="quinidine" /><entity charOffset="84-94" id="DDI-PubMed.22283559.s1.e2" text="paroxetine" /><pair ddi="false" e1="DDI-PubMed.22283559.s1.e0" e2="DDI-PubMed.22283559.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22283559.s1.e0" e2="DDI-PubMed.22283559.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22283559.s1.e0" e2="DDI-PubMed.22283559.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22283559.s1.e1" e2="DDI-PubMed.22283559.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22283559.s1.e1" e2="DDI-PubMed.22283559.s1.e2" /></sentence><sentence text="The novel combination of dextromethorphan (DM) and quinidine (Q) [DMQ] has been extensively studied in well controlled clinical trials as treatment for pseudobulbar affect (PBA), and is the first US Food and Drug Administration (FDA)-approved treatment for this indication"><entity charOffset="25-41" id="DDI-PubMed.22283559.s2.e0" text="dextromethorphan" /><entity charOffset="43-45" id="DDI-PubMed.22283559.s2.e1" text="DM" /><entity charOffset="51-60" id="DDI-PubMed.22283559.s2.e2" text="quinidine" /><entity charOffset="66-74" id="DDI-PubMed.22283559.s2.e3" text="DM" /><pair ddi="false" e1="DDI-PubMed.22283559.s2.e0" e2="DDI-PubMed.22283559.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22283559.s2.e0" e2="DDI-PubMed.22283559.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22283559.s2.e0" e2="DDI-PubMed.22283559.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22283559.s2.e0" e2="DDI-PubMed.22283559.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22283559.s2.e1" e2="DDI-PubMed.22283559.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22283559.s2.e1" e2="DDI-PubMed.22283559.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22283559.s2.e1" e2="DDI-PubMed.22283559.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22283559.s2.e2" e2="DDI-PubMed.22283559.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22283559.s2.e2" e2="DDI-PubMed.22283559.s2.e3" /></sentence><sentence text=" The approved dosage of DMQ is DM 20 mg and Q 10 mg twice daily"><entity charOffset="24-25" id="DDI-PubMed.22283559.s3.e0" text="DM" /><entity charOffset="31-32" id="DDI-PubMed.22283559.s3.e1" text="DM" /><pair ddi="false" e1="DDI-PubMed.22283559.s3.e0" e2="DDI-PubMed.22283559.s3.e0" /><pair ddi="false" e1="DDI-PubMed.22283559.s3.e0" e2="DDI-PubMed.22283559.s3.e1" /></sentence><sentence text=" DM is metabolized via cytochrome P450 2D6 (CYP2D6); Q is a CYP2D6 inhibitor used to increase DM plasma concentrations"><entity charOffset="1-2" id="DDI-PubMed.22283559.s4.e0" text="DM" /><entity charOffset="94-95" id="DDI-PubMed.22283559.s4.e1" text="DM" /><pair ddi="false" e1="DDI-PubMed.22283559.s4.e0" e2="DDI-PubMed.22283559.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22283559.s4.e0" e2="DDI-PubMed.22283559.s4.e1" /></sentence><sentence text=" Paroxetine is both a substrate and inhibitor of CYP2D6"><entity charOffset="1-11" id="DDI-PubMed.22283559.s5.e0" text="Paroxetine" /></sentence><sentence text=" This trial evaluated the effect of DMQ at a dose of DM 30 mg and Q 30 mg twice daily on the steady-state pharmacokinetics of paroxetine 20 mg daily and the effects of paroxetine on the steady-state pharmacokinetics of DMQ in healthy volunteers"><entity charOffset="126-136" id="DDI-PubMed.22283559.s6.e0" text="paroxetine" /><entity charOffset="168-178" id="DDI-PubMed.22283559.s6.e1" text="paroxetine" /><entity charOffset="36-45" id="DDI-PubMed.22283559.s6.e2" text="DM" /><entity charOffset="53-62" id="DDI-PubMed.22283559.s6.e3" text="DM" /><entity charOffset="219-228" id="DDI-PubMed.22283559.s6.e4" text="DM" /><pair ddi="false" e1="DDI-PubMed.22283559.s6.e2" e2="DDI-PubMed.22283559.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22283559.s6.e2" e2="DDI-PubMed.22283559.s6.e3" /><pair ddi="false" e1="DDI-PubMed.22283559.s6.e2" e2="DDI-PubMed.22283559.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22283559.s6.e2" e2="DDI-PubMed.22283559.s6.e1" /><pair ddi="false" e1="DDI-PubMed.22283559.s6.e2" e2="DDI-PubMed.22283559.s6.e4" /><pair ddi="false" e1="DDI-PubMed.22283559.s6.e3" e2="DDI-PubMed.22283559.s6.e3" /><pair ddi="false" e1="DDI-PubMed.22283559.s6.e3" e2="DDI-PubMed.22283559.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22283559.s6.e3" e2="DDI-PubMed.22283559.s6.e1" /><pair ddi="false" e1="DDI-PubMed.22283559.s6.e3" e2="DDI-PubMed.22283559.s6.e4" /><pair ddi="false" e1="DDI-PubMed.22283559.s6.e0" e2="DDI-PubMed.22283559.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22283559.s6.e0" e2="DDI-PubMed.22283559.s6.e1" /><pair ddi="false" e1="DDI-PubMed.22283559.s6.e0" e2="DDI-PubMed.22283559.s6.e4" /><pair ddi="false" e1="DDI-PubMed.22283559.s6.e1" e2="DDI-PubMed.22283559.s6.e1" /><pair ddi="false" e1="DDI-PubMed.22283559.s6.e1" e2="DDI-PubMed.22283559.s6.e4" /></sentence><sentence text="" /><sentence text="This was an open-label, randomized, parallel-group, 20-day trial" /><sentence text=" Drug plasma concentrations were analysed following monotherapy and concomitant (DMQ + paroxetine) therapy"><entity charOffset="81-82" id="DDI-PubMed.22283559.s9.e0" text="DM" /></sentence><sentence text=" Participants were 27 healthy adults who were randomized in a 1 : 1 fashion to one of two groups" /><sentence text=" Group 1 received paroxetine 20 mg once daily for 12 days to attain steady state, at which point DMQ 30 mg/30 mg twice daily was added for 8 days"><entity charOffset="18-28" id="DDI-PubMed.22283559.s11.e0" text="paroxetine" /><entity charOffset="97-106" id="DDI-PubMed.22283559.s11.e1" text="DM" /><pair ddi="false" e1="DDI-PubMed.22283559.s11.e0" e2="DDI-PubMed.22283559.s11.e0" /><pair ddi="false" e1="DDI-PubMed.22283559.s11.e0" e2="DDI-PubMed.22283559.s11.e1" /></sentence><sentence text=" Group 2 received DMQ 30 mg/30 mg twice daily for 8 days to attain steady state, at which point paroxetine 20 mg once daily was added for 12 days"><entity charOffset="96-106" id="DDI-PubMed.22283559.s12.e0" text="paroxetine" /><entity charOffset="18-27" id="DDI-PubMed.22283559.s12.e1" text="DM" /><pair ddi="false" e1="DDI-PubMed.22283559.s12.e1" e2="DDI-PubMed.22283559.s12.e1" /><pair ddi="false" e1="DDI-PubMed.22283559.s12.e1" e2="DDI-PubMed.22283559.s12.e0" /></sentence><sentence text=" The primary endpoints were the 90% confidence intervals (CIs) for the ratio of the area under the plasma concentration-time curve (AUC) during concomitant therapy versus monotherapy" /><sentence text=" Safety and tolerability measures including adverse events (AEs) were also assessed" /><sentence text="" /><sentence text="The 90% CIs of the AUCs were outside of the predefined range [0" /><sentence text="80, 1" /><sentence text="25] for all analytes, indicating a drug-drug interaction" /><sentence text=" In group 1 (n = 14), addition of DMQ to paroxetine resulted in a 30% increase in mean plasma exposure of paroxetine (AUC up to 24 hours)"><entity charOffset="41-51" id="DDI-PubMed.22283559.s19.e0" text="paroxetine" /><entity charOffset="106-116" id="DDI-PubMed.22283559.s19.e1" text="paroxetine" /><entity charOffset="34-43" id="DDI-PubMed.22283559.s19.e2" text="DM" /><pair ddi="false" e1="DDI-PubMed.22283559.s19.e2" e2="DDI-PubMed.22283559.s19.e2" /><pair ddi="false" e1="DDI-PubMed.22283559.s19.e2" e2="DDI-PubMed.22283559.s19.e0" /><pair ddi="false" e1="DDI-PubMed.22283559.s19.e2" e2="DDI-PubMed.22283559.s19.e1" /><pair ddi="false" e1="DDI-PubMed.22283559.s19.e0" e2="DDI-PubMed.22283559.s19.e0" /><pair ddi="false" e1="DDI-PubMed.22283559.s19.e0" e2="DDI-PubMed.22283559.s19.e1" /></sentence><sentence text=" In group 2 (n = 13), addition of paroxetine to DMQ resulted in increases in mean plasma exposure (AUC up to 12 hours) of 50% for DM and 40% for Q, and a decrease of 12"><entity charOffset="34-44" id="DDI-PubMed.22283559.s20.e0" text="paroxetine" /><entity charOffset="48-57" id="DDI-PubMed.22283559.s20.e1" text="DM" /><entity charOffset="130-139" id="DDI-PubMed.22283559.s20.e2" text="DM" /><pair ddi="false" e1="DDI-PubMed.22283559.s20.e0" e2="DDI-PubMed.22283559.s20.e0" /><pair ddi="false" e1="DDI-PubMed.22283559.s20.e0" e2="DDI-PubMed.22283559.s20.e1" /><pair ddi="false" e1="DDI-PubMed.22283559.s20.e0" e2="DDI-PubMed.22283559.s20.e2" /><pair ddi="false" e1="DDI-PubMed.22283559.s20.e1" e2="DDI-PubMed.22283559.s20.e1" /><pair ddi="false" e1="DDI-PubMed.22283559.s20.e1" e2="DDI-PubMed.22283559.s20.e2" /></sentence><sentence text="3% for dextrorphan, the metabolite of DM"><entity charOffset="7-18" id="DDI-PubMed.22283559.s21.e0" text="dextrorphan" /><entity charOffset="38-48" id="DDI-PubMed.22283559.s21.e1" text="DM" /><pair ddi="false" e1="DDI-PubMed.22283559.s21.e0" e2="DDI-PubMed.22283559.s21.e0" /><pair ddi="false" e1="DDI-PubMed.22283559.s21.e0" e2="DDI-PubMed.22283559.s21.e1" /></sentence><sentence text=" The incidence of AEs was higher with paroxetine monotherapy and combination therapy, compared with DMQ given alone (30"><entity charOffset="38-48" id="DDI-PubMed.22283559.s22.e0" text="paroxetine" /><entity charOffset="100-109" id="DDI-PubMed.22283559.s22.e1" text="DM" /><pair ddi="false" e1="DDI-PubMed.22283559.s22.e0" e2="DDI-PubMed.22283559.s22.e0" /><pair ddi="false" e1="DDI-PubMed.22283559.s22.e0" e2="DDI-PubMed.22283559.s22.e1" /></sentence><sentence text="8% with DMQ alone vs 83"><entity charOffset="8-9" id="DDI-PubMed.22283559.s23.e0" text="DM" /></sentence><sentence text="3% following addition of paroxetine, and 78"><entity charOffset="25-35" id="DDI-PubMed.22283559.s24.e0" text="paroxetine" /></sentence><sentence text="6% with paroxetine alone vs 64"><entity charOffset="8-18" id="DDI-PubMed.22283559.s25.e0" text="paroxetine" /></sentence><sentence text="3% following addition of DMQ)"><entity charOffset="25-34" id="DDI-PubMed.22283559.s26.e0" text="DM" /></sentence><sentence text=" Three subjects discontinued due to AEs, and no serious AEs were reported" /><sentence text="" /><sentence text="The addition of DMQ 30 mg/30 mg twice daily to paroxetine increased steady-state paroxetine plasma concentrations and addition of paroxetine to DMQ 30 mg/30 mg twice daily increased steady-state plasma concentrations of DM and Q, indicating a potential interaction"><entity charOffset="47-57" id="DDI-PubMed.22283559.s29.e0" text="paroxetine" /><entity charOffset="81-91" id="DDI-PubMed.22283559.s29.e1" text="paroxetine" /><entity charOffset="130-140" id="DDI-PubMed.22283559.s29.e2" text="paroxetine" /><entity charOffset="16-25" id="DDI-PubMed.22283559.s29.e3" text="DM" /><entity charOffset="144-153" id="DDI-PubMed.22283559.s29.e4" text="DM" /><entity charOffset="220-229" id="DDI-PubMed.22283559.s29.e5" text="DM" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e3" e2="DDI-PubMed.22283559.s29.e3" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e3" e2="DDI-PubMed.22283559.s29.e0" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e3" e2="DDI-PubMed.22283559.s29.e1" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e3" e2="DDI-PubMed.22283559.s29.e2" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e3" e2="DDI-PubMed.22283559.s29.e4" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e3" e2="DDI-PubMed.22283559.s29.e5" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e0" e2="DDI-PubMed.22283559.s29.e0" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e0" e2="DDI-PubMed.22283559.s29.e1" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e0" e2="DDI-PubMed.22283559.s29.e2" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e0" e2="DDI-PubMed.22283559.s29.e4" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e0" e2="DDI-PubMed.22283559.s29.e5" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e1" e2="DDI-PubMed.22283559.s29.e1" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e1" e2="DDI-PubMed.22283559.s29.e2" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e1" e2="DDI-PubMed.22283559.s29.e4" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e1" e2="DDI-PubMed.22283559.s29.e5" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e2" e2="DDI-PubMed.22283559.s29.e2" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e2" e2="DDI-PubMed.22283559.s29.e4" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e2" e2="DDI-PubMed.22283559.s29.e5" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e4" e2="DDI-PubMed.22283559.s29.e4" /><pair ddi="false" e1="DDI-PubMed.22283559.s29.e4" e2="DDI-PubMed.22283559.s29.e5" /></sentence><sentence text=" Thus, patients should be monitored for AEs and dosage adjustment considered when combining these two agents" /><sentence text="" /></document>